-
公开(公告)号：US20210095026A1
公开(公告)日：2021-04-01
申请号：US17074269
申请日：2020-10-19
Applicant: ANAPTYSBIO, INC.
Inventor： Helen Toni Jun , Marilyn Kehry , Peter Bowers , David J. King
IPC: C07K16/28 , A61P31/00 , A61P35/00 , A61K39/395
Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using, the LAG-3-binding, agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.
-
公开(公告)号：US10526410B2
公开(公告)日：2020-01-07
申请号：US15567045
申请日：2016-04-15
Applicant: AnaptysBio, Inc.
Inventor： Peter Bowers , Andrew John McKnight , David J. King , Marco Londei
IPC: C07K16/28 , A61P37/06 , A61P29/00 , A61K39/395 , A61K39/00
Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
-
3.发明公开公开(公告)号：US20240158495A1
公开(公告)日：2024-05-16
申请号：US18153749
申请日：2023-01-12
Applicant: Tesaro, Inc. , Anaptysbio, Inc.
Inventor： Helen Toni Jun , Marilyn Kehry , Peter Bowers , David J. King , Dmitri Bobilev , Srimoyee Ghosh , Baochuan Huang , David Jenkins
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61P35/00 , A61K2039/505
Abstract: The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease.
-
公开(公告)号：US20220135670A1
公开(公告)日：2022-05-05
申请号：US16608111
申请日：2018-04-27
Applicant: TESARO, INC. , ANAPTYSBIO, INC.
Inventor： Helen Toni Jun , Marilyn Kehry , Peter Bowers , David J. King , Dmitri Bobilev , Srimoyee Ghosh , Baochuan Huang , David Jenkins
IPC: C07K16/28 , A61K45/06 , A61K39/395 , A61P35/00
Abstract: The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease.
-
公开(公告)号：US11130814B2
公开(公告)日：2021-09-28
申请号：US16686373
申请日：2019-11-18
Applicant: AnaptysBio, Inc.
Inventor： Peter Bowers , Andrew John McKnight , David J. King , Marco Londei
IPC: C07K16/28 , A61P37/06 , A61P29/00 , A61K39/395 , A61K39/00
Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
-
Patent Agency Ranking
公开(公告)号：US20150118226A1
公开(公告)日：2015-04-30
申请号：US14587479
申请日：2014-12-31
Applicant: ANAPTYSBIO, INC.
Inventor： David J. King , Peter Bowers , Robert A. Horlick , Tamlyn Yee Neben
IPC: C07K16/22
CPC classification number: C07K16/22 , C07H21/04 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
Abstract translation: 本发明涉及分离的免疫球蛋白重链多肽和结合神经生长因子（NGF）的分离的免疫球蛋白轻链多肽。 本发明提供了包含上述免疫球蛋白重链多肽和免疫球蛋白轻链多肽的NGF结合剂。 本发明还提供使用NGF结合剂治疗NGF介导的疾病的载体，组合物和方法。
-
公开(公告)号：US09951126B2
公开(公告)日：2018-04-24
申请号：US14587479
申请日：2014-12-31
Applicant: AnaptysBio, Inc.
Inventor： David J. King , Peter Bowers , Robert A. Horlick , Tamlyn Yee Neben
CPC classification number: C07K16/22 , C07H21/04 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
-
公开(公告)号：US08926978B2
公开(公告)日：2015-01-06
申请号：US13659308
申请日：2012-10-24
Applicant: AnaptysBio, Inc.
Inventor： David J. King , Peter Bowers , Robert A. Horlick , Tamlyn Yee Neben
CPC classification number: C07K16/22 , C07H21/04 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
Abstract translation: 本发明涉及分离的免疫球蛋白重链多肽和结合神经生长因子（NGF）的分离的免疫球蛋白轻链多肽。 本发明提供了包含上述免疫球蛋白重链多肽和免疫球蛋白轻链多肽的NGF结合剂。 本发明还提供使用NGF结合剂治疗NGF介导的疾病的载体，组合物和方法。
-
9.发明申请USE OF SOMATIC HYPERMUTATION TO CREATE INSERTION AND DELETION MUTATIONS IN VITRO 审中-公开使用SOMATIC HYPERMUTATION创建体内插入和删除突变公开(公告)号：US20130102031A1
公开(公告)日：2013-04-25
申请号：US13655793
申请日：2012-10-19
Applicant: AnaptysBio, Inc.
Inventor： David J. King , Peter Bowers , Robert A. Horlick
CPC classification number: G01R1/02 , B05D1/18 , B05D1/26 , B05D1/327 , B05D3/067 , B05D3/068 , C09D5/16 , C09D133/04 , C12N9/78 , C12N15/102 , C12P19/34 , G01B7/003 , G01D5/24 , G01R27/2605 , G06F3/044 , G06F2203/04103 , G06F2203/04104 , Y02P20/52
Abstract: The invention is directed to an in vitro method for introducing one or more insertion mutations and/or one or more deletion mutations in a nucleic acid sequence encoding a polypeptide. The method comprises contacting a cell in vitro with a nucleic acid sequence, and expressing Activation Induced Cytidine Deaminase (AID) in the cell. The invention also is directed to a method of producing an immunoglobulin.
Abstract translation: 本发明涉及用于在编码多肽的核酸序列中引入一个或多个插入突变和/或一个或多个缺失突变的体外方法。 该方法包括使体外细胞与核酸序列接触，并在细胞中表达激活诱导的胞苷脱氨酶（AID）。 本发明还涉及生产免疫球蛋白的方法。
-
公开(公告)号：US20130101601A1
公开(公告)日：2013-04-25
申请号：US13659308
申请日：2012-10-24
Applicant: AnaptysBio, Inc.
Inventor： David J. King , Peter Bowers , Robert A. Horlick , Tamlyn Yee Neben
CPC classification number: C07K16/22 , C07H21/04 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.016 seconds)
